Pushkal Garg, EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 4,627 shares at $328.92 ($1.5M) on 2026-02-27, disclosed to the SEC on 2026-03-02.
Seasonal sale ($1.5M) by EVP Chief R&D — this insider has traded ALNY in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $328.92 | 127 | $42K | 2.7% |
| 2 | $330.73 | 2,259 | $747K | 48.7% |
| 3 | $331.49 | 1,159 | $384K | 25.1% |
| 4 | $332.48 | 942 | $313K | 20.4% |
| 5 | $334.39 | 140 | $47K | 3.1% |
| Total | $331.34 avg | 4,627 |
| $1.5M |
| 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |
| ALNY | SELL | 2025-10-03 | $5.3M | — | Filing → |